Daniil Stroyakovskiy
A5071263994- HER2/EGFR in Cancer Research
- Melanoma and MAPK Pathways
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Advanced Breast Cancer Therapies
- Breast Cancer Treatment Studies
- Cutaneous Melanoma Detection and Management
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Monoclonal and Polyclonal Antibodies Research
- Computational Drug Discovery Methods
- Synthesis of Tetrazole Derivatives
- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Peptidase Inhibition and Analysis
- Biosimilars and Bioanalytical Methods
- Radiopharmaceutical Chemistry and Applications
- Economic and Financial Impacts of Cancer
- Metastasis and carcinoma case studies
- Genetic factors in colorectal cancer
- Head and Neck Cancer Studies
Moscow City Oncology Hospital №62
2016-2025
Chungbuk National University Hospital
2024
Samsung Medical Center
2018-2024
Asan Medical Center
2024
Seoul National University Bundang Hospital
2024
Yonsei University
2024
National Cancer Institute
2024
Palacký University Olomouc
2018
Roche (Switzerland)
2009-2018
Sana Klinikum Offenbach
2018
The cancer-cell-killing property of atezolizumab may be enhanced by the blockade vascular endothelial growth factor-mediated immunosuppression with bevacizumab. This open-label, phase 3 study evaluated plus bevacizumab chemotherapy in patients metastatic nonsquamous non-small-cell lung cancer (NSCLC) who had not previously received chemotherapy.We randomly assigned to receive carboplatin paclitaxel (ACP), (BCP), or BCP (ABCP) every weeks for four six cycles, followed maintenance therapy...
The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset resistance observed inhibitors alone. This randomized phase 3 study evaluated combination inhibitor vemurafenib cobimetinib.We randomly assigned 495 previously untreated unresectable locally advanced metastatic V600 mutation-positive receive cobimetinib (combination group) placebo (control group). primary end point was investigator-assessed...
Combined BRAF and MEK inhibition, as compared with inhibition alone, delays the emergence of resistance reduces toxic effects in patients who have melanoma V600E or V600K mutations.
Patients who have unresectable or metastatic melanoma with a BRAF V600E V600K mutation prolonged progression-free survival and overall when receiving treatment inhibitors plus MEK inhibitors. However, long-term clinical outcomes in these patients remain undefined. To determine 5-year rates characteristics of the durable benefit, we sought to review data from randomized trials combination therapy
Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall (OS) with combination dabrafenib trametinib versus monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy safety after ≥36-month follow-up for all living patients.This double-blind, phase 3 enrolled previously untreated patients unresectable stage IIIC or IV Patients were randomized receive (150 mg twice daily) plus (2 once...
Cytotoxic agents have immunomodulatory effects, providing a rationale for combining atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1]) with chemotherapy. The randomized phase III IMpower131 study (NCT02367794) evaluated platinum-based chemotherapy in stage IV squamous NSCLC.A total of 1021 patients were 1:1:1 to receive atezolizumab+carboplatin+paclitaxel (A+CP) (n = 338), atezolizumab+carboplatin+nab-paclitaxel (A+CnP) 343), or carboplatin+nab-paclitaxel (CnP) 340) four six 21-day...
IntroductionWe report the final overall survival (OS) analyses of atezolizumab-carboplatin-paclitaxel (ACP [experimental arm]) and OS data with approximately 39.8 months median follow-up atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) versus bevacizumab-carboplatin-paclitaxel (BCP) in chemotherapy-naive patients metastatic nonsquamous NSCLC phase 3 IMpower150 study (NCT02366143).MethodsIn this randomized, open-label (N = 1202), coprimary end points included investigator-assessed...
PURPOSE Trastuzumab deruxtecan (T-DXd) is a human epidermal growth factor 2 (HER2)–directed antibody-drug conjugate approved in HER2-expressing breast and gastric cancers HER2-mutant non–small-cell lung cancer. Treatments are limited for other solid tumors. METHODS This open-label phase II study evaluated T-DXd (5.4 mg/kg once every 3 weeks) (immunohistochemistry [IHC] 3+/2+ by local or central testing) locally advanced metastatic disease after ≥1 systemic treatment without alternative...
LBA9000 Background: Atezolizumab (atezo; anti–PD-L1) demonstrated OS benefit vs docetaxel in 2L+ NSCLC regardless of PD-L1 status or tumor histology. Because cytotoxic agents can exhibit positive immunomodulatory effects, combining atezo with chemotherapy may further improve outcomes. IMpower131 (NCT02367794) was designed to evaluate + carboplatin (carbo) paclitaxel (pac) nab-paclitaxel (nab-pac) 1L stage IV squamous NSCLC. Methods: Patients (pts) were randomized 1:1:1 Arm A (atezo 1200 mg...
The KRISTINE study compared neoadjuvant trastuzumab emtansine plus pertuzumab (T-DM1+P) with docetaxel, carboplatin, P (TCH+P) for the treatment human epidermal growth factor receptor 2-positive stage II to III breast cancer. T-DM1+P led a lower pathologic complete response rate (44.4%
In a previous phase 3 trial, treatment with trifluridine-tipiracil (FTD-TPI) prolonged overall survival among patients metastatic colorectal cancer. Preliminary data from single-group and randomized 2 trials suggest that FTD-TPI in addition to bevacizumab has the potential extend survival.We randomly assigned, 1:1 ratio, adult who had received no more than two chemotherapy regimens for of advanced cancer receive plus (combination group) or alone (FTD-TPI group). The primary end point was...
Abstract Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall (OS) with addition of cobimetinib to vemurafenib compared in patients previously untreated BRAFV600 mutation–positive advanced melanoma. We report long-term follow-up coBRIM, at least 5 years since the last patient was randomized. Patients Methods: Eligible were 1:1 receive either oral (60 mg once daily on days 1–21 each 28-day cycle) or placebo combination...
Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with alone. These observations are supported by translational evidence suggesting that immune checkpoint inhibitors targeted therapy may improve treatment outcomes in patients BRAF V600-mutant metastatic melanoma. COMBI-i is a phase III trial evaluating spartalizumab, antibody, (sparta-DabTram), versus placebo (placebo-DabTram)...
Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)–positive, human epidermal growth factor 2 (HER2)–negative advanced breast cancer. Whether this cancer extends early is unclear. Download PDF of the Research Summary. In international, open-label, randomized, phase 3 trial, we randomly assigned HR-positive, HER2-negative 1:1 ratio receive ribociclib (at dose 400 mg per day for weeks, followed by 1 week off, years) plus nonsteroidal...
Interim analyses of the IMmotion151 trial (A Study Atezolizumab in Combination With Bevacizumab Versus Sunitinib Participants Untreated Advanced Renal Cell Carcinoma) reported improved progression-free survival (PFS) for patients with programmed death ligand 1-positive (PD-L1+) metastatic renal cell carcinoma (mRCC) receiving PD-L1 inhibitor atezolizumab plus vascular endothelial growth factor (VEGF) bevacizumab vs receptor tyrosine kinase sunitinib. Overall (OS) results were immature at...